Skip to content
value.today

Kala Pharmaceuticals

KALA
$3 Mmarket cap on Oct 29, 2026-81.7% since Jan 2024
1M
-50.0%
Compare
World rank
#27,306
Revenue
—
For year ending December-2025
Net income
$-27 M
SEC filing
Employees
—

Kala Pharmaceuticals in brief

Kala Pharmaceuticals is a listed company in the Biotechnology industry, based in Arlington, Massachusetts, USA. It was founded in 2009. Its market value was $3 M on 29 October 2026, which makes it the 27,306th largest listed company in the world and the 4,450th largest in the USA on this site. Avraham Minkowitz is its chief executive. Its shares trade under the symbol KALA (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Kala Pharmaceuticals

Kala Pharmaceuticals is a Biopharmaceutical company committed to advancing the treatment of eye diseases. The company annual revenue is 6.36 million USD and 205 employees as on 2020. The headquarters is in USA.

Kala Pharmaceuticals timeline

5 events, 2009–2023
  1. 2009
  2. 🏁
    · approximate
    Founded
  3. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  4. 2017
  5. 🔔
    Initial public offering as Kala Pharmaceuticals, Inc.
    Final prospectus filed with the SEC on 20 July 2017; shares registered for exchange trading on 14 July 2017.
  6. 2021
  7. 💰
    Record revenue of $11 million
    FY2021, the highest of the 4 years on record.
  8. 2023
  9. ✎
    Renamed KALA BIO, Inc.
    Formerly Kala Pharmaceuticals, Inc..

Events of Kala Pharmaceuticals from the company record, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$103 M$205 M$308 M$410 M2020202120222023202420252026

World rank over time

▼ down 9,571 places since 2020
2020-01-01: #17738#17,73820202021-01-01: #12549#12,54920212022-01-07: #24630#24,63020222022-12-25: #17577#17,57720222023-07-30: #26940#26,94020232024-01-05: #29114#29,11420242026-03-08: #8614#8,61420262026-08-01: #22013#22,01320262026-10-06: #26539#26,53920262026-10-29: #27309#27,3092026

Rank in USA: #3,540 (Jan 2020) · #2,975 (Jan 2021) · #4,676 (Jan 2022) · #3,590 (Dec 2022) · #4,942 (Jul 2023) · #4,375 (Jan 2024) · #1,597 (Mar 2026) · #3,963 (Aug 2026) · #4,308 (Oct 2026) · #4,452 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
0.5×
Free cash flow yield
-2702.9%
Net margin
—
Operating margin
—
Return on equity
-385.4%
Liabilities / assets
26.2%
Net debt
$-22M
Revenue growth
-65.4%
R&D / revenue
453.7%

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue —, net income $-67M—FY18Fiscal year ending Dec 2019: revenue $6M, net income $-94M$6MFY19Fiscal year ending Dec 2020: revenue $6M, net income $-104M$6MFY20Fiscal year ending Dec 2021: revenue $11M, net income $-143M$11MFY21Fiscal year ending Dec 2022: revenue $4M, net income $-45M$4MFY22Fiscal year ending Dec 2023: revenue —, net income $-42M—FY23Fiscal year ending Dec 2024: revenue —, net income $-39M—FY24Fiscal year ending Dec 2025: revenue —, net income $-27M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-39M$-27M—
Dec 2024——$-41M$-39M—
Dec 2023——$-40M$-42M—
Dec 2022$4M-65.4%$-82M$-45M-1152.2%
Dec 2021$11M+76.7%$-130M$-143M-1268.7%
Dec 2020$6M+4.8%$-96M$-104M-1640.4%
Dec 2019$6M—$-88M$-94M-1554.4%
Dec 2018——$-65M$-67M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-32M——$-3.31—
Dec 2024$-29M——$-10.15—
Dec 2023$-28M——$-17.35—
Dec 2022$-79M——$-29.48—
Dec 2021$-108M——$-108.32—
Dec 2020$-91M——$-1.99—
Dec 2019$-93M$1M$-94M$-2.76—
Dec 2018$-54M$2M$-56M$-2.49—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Sep 2024: revenue —, net income $-9M—Sep ’24Three months to Dec 2024 (from the annual report): revenue —, net income $-8M—Dec ’24Three months to Mar 2025: revenue —, net income $-9M—Mar ’25Three months to Jun 2025: revenue —, net income $-11M—Jun ’25Three months to Sep 2025: revenue —, net income $-8M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $1M—Dec ’25Three months to Mar 2026: revenue —, net income $-2M—Mar ’26Three months to Jun 2026: revenue —, net income $-2M—Jun ’26

Latest quarter to Jun 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.

SEC filings

Official filings of Kala Pharmaceuticals with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-39 M
Net income
$-27 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$9 M
Total liabilities
$2 M
Total equity
$7 M

As of December-2025

Top 16 institutional investors in Kala Pharmaceuticals#

As of Sep 30, 2026
16 institutions held 860,045 shares (about 4.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 4.4%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 16 largest institutional investors in Kala Pharmaceuticals
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Capital Management LLC220,6230 (0.00%)1.14%$0 MNov 13, 2026
2Geode Capital Management, LLC173,948+28,796 (+19.84%)0.90%$0 MNov 6, 2026
3Vanguard Fiduciary Trust Co101,3960 (0.00%)0.52%$0 MNov 13, 2026
4State Street Corp88,5700 (0.00%)0.46%$0 MNov 12, 2026
5Renaissance Technologies LLC81,100New0.42%$0 MNov 12, 2026
6Susquehanna International Group, LLP79,831New0.41%$0 MNov 16, 2026
7BlackRock, Inc.71,446-96 (-0.13%)0.37%$0 MNov 13, 2026
8Northern Trust Corp41,6060 (0.00%)0.22%$0 MNov 16, 2026
9UBS Group AG1,345-7,712 (-85.15%)0.01%$0 MNov 10, 2026
10Morgan Stanley124+96 (+342.86%)0.00%$0 MNov 13, 2026
11Tower Research Capital LLC (TRC)45-571 (-92.69%)0.00%$0 MNov 16, 2026
12Bank Julius Baer & Co. Ltd, Zurich5New0.00%$0 MOct 29, 2026
13Berthel, Fisher & Company Financial Services, Inc.3New0.00%$0 MNov 13, 2026
14Barclays PLC1-607 (-99.84%)0.00%$0 MNov 6, 2026
15Northwestern Mutual Wealth Management Co1New0.00%$0 MNov 13, 2026
16Caitong International Asset Management Co., Ltd1-9 (-90.00%)0.00%$0 MOct 29, 2026

Mutual funds holding Kala Pharmaceuticals#

6 funds hold shares worth $0 M (about 1.2% of the company). Since their previous reports 1 added shares and 5 sold, buying $0 M net.
Mutual funds holding Kala Pharmaceuticals
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.220,623$0 M1.1%<0.01%+264%Jun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC5,633$0 M0.03%<0.01%−12%May 31, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC3,822$0 M0.02%<0.01%−90%May 31, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC355$0 M<0.01%<0.01%−52%Jun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC236$0 M<0.01%<0.01%−98%May 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC152$0 M<0.01%<0.01%−98%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 6 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Kala Pharmaceuticals#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
30
since
$2.0 M-$958 K$0Jan 2024: bought $0 (0 trades), sold $69 K (6 trades)Jan 24May 2024: bought $0 (0 trades), sold $82 K (5 trades)MayJun 2024: bought $0 (0 trades), sold $164 K (5 trades)JunDec 2024: bought $2.0 M (2 trades), sold $0 (0 trades)DecJan 2025: bought $0 (0 trades), sold $106 K (5 trades)Jan 25Jun 2025: bought $0 (0 trades), sold $204 K (10 trades)JunSep 2025: bought $0 (0 trades), sold $347 K (2 trades)SepOct 2025: bought $0 (0 trades), sold $958 K (8 trades)Oct
Bought (open market)Sold (open market)Hover a month for the totals
Kala Pharmaceuticals: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Mark T. IwickiDirectorSell-154,894$0.810$125 K103,540Form 4
filed Mary ReumuthCHIEF FINANCIAL OFFICERSell-967$0.820$79328,906Form 4
filed Todd BazemoreDirectorSell-47,768$0.830$40 K35,932Form 4
filed Mary ReumuthCHIEF FINANCIAL OFFICERSell-32,230$0.830$27 K29,873Form 4
filed Darius KharabiCHIEF BUSINESS OFFICERSell-20,806$0.830$17 K41,760Form 4
filed Romulus K. BrazzellSEE REMARKSSell-46,748$0.830$39 K35,952Form 4
filed Julian BakerFormer 10% ownerSellindirect-50,640$1.380$70 K46,480Form 4
filed Julian BakerFormer 10% ownerSellindirect-462,967$1.380$639 K425,006Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Kala Pharmaceuticals#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
382,804
1.81 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-50 reverse split ; 1-for-50 reverse split ; 1-for-5.21 reverse split

Trading halts

  • 2026-11-14 00:50 UTC, code T3, resumed 14:00 UTC
  • 2026-08-28 13:38 UTC, code LUDP, resumed 13:43 UTC
  • 2026-05-08 23:50 UTC, code T3, resumed 13:00 UTC
  • 2025-12-04 15:45 UTC, code LUDP, resumed 15:50 UTC
  • 2025-09-29 14:57 UTC, code LUDP, resumed 15:02 UTC

Fails to deliver

  • : 29,972 shares at $0.18
  • : 20,045 shares at $0.18
  • : 2,386 shares at $0.19
  • : 516 shares at $0.36
  • : 9,512 shares at $0.42

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Kala Pharmaceuticals scorecard#

Passes 3 of the 12 checks that could be worked out: strongest in valuation (1 of 3), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 29, 2026.

  • Valuation1 of 3
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.5×Price to book 0.5× against Biotechnology's median of 2.9×.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-3.31 vs -10.15Diluted EPS -3.31 in fiscal 2025 against -10.15 the year before (report's currency).
    • ✓Net income higher than five years earlier-$27 M-$27 M in fiscal 2025 against -$104 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$27 MNet income -$27 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-279.1%-279.1% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities3.8×Current ratio 3.81 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • ✗Operating income covers interest five times-11.9×Operating income -11.9 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year114.7%Diluted shares up 114.7% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Kala Pharmaceuticals: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Kala Pharmaceuticals: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0003.9116.46.1—00
Research and development19221918121827292925
Selling, general and administrative——216510581653511—
General and administrative241821—————117.6
Operating expenses3941408614110394654033
Operating income−39−41−40−82−130−96−88−65−40−33
Interest and finance income1.12.12.70.70.10.52.41.70.50.1
Interest expense and finance costs3.35.85.87.38.48.68.53.31.00.8
Other non-operating income (expense)122.5−2.537−12—————
Income tax0000000000
Net income including minority interests−27−39−42−45−143−104−94−67−42−33
Net income attributable to shareholders−27−39−42−45−143−104−94−67−42−33
Earnings per share, basic-3.31-10.15-17.35-29.48-108.32r-1.99-2.76-2.49-3.71r-28.07
Earnings per share, diluted-3.31-10.15-17.35-29.48-108.32r-1.99-2.76-2.49-3.71r-28.07
Shares, weighted average (basic)8.13.82.41.51.3r52————
Shares, weighted average (diluted)8.13.82.41.51.3r52342711r1.2
Balance sheet
Cash and cash equivalents7.651517092778517111545
Short-term investments—————76————
Receivables———0.2159.612———
Inventory————8.65.24.64.1——
Other current assets1.91.62.07.9r6.23.03.80.50.2r0.0
Current assets9.553538612417110517711546
Property, plant and equipment—0.70.80.42.73.22.72.20.80.6
Right-of-use (leased) assets—1.72.00.01.32830300.4—
Total assets9.5555687139222154221117r46
Accounts payable1.00.60.92.84.91.72.55.41.21.0
Debt due within a year—10—5.0————6.70.6
Current liabilities2.5178.3263722251715r5.5
Long-term debt—20343879727170129.1
Lease liabilities (non-current)—1.41.8—0.5—————
Non-current liabilities—26404285991009912r10
Total liabilities2.543486812312212511627r16
Retained earnings−695−668−629−587−542−400−295−201−134−92
Shareholders' equity7.0127.519171003010590−88
Total liabilities and equity9.5555687139222154221117r46
Shares outstanding0.6r6.12.81.71.3r593634251.2
Cash-flow statement
Depreciation and amortization0.30.30.30.51.00.90.8———
Share-based compensation7.08.47.57.0161310.08.63.62.1
Cash from operating activities−32−29−28−79−108−91−93−54−34−27
Capital expenditure——————−1.3−1.6−0.5−0.2
Acquisitions, net of cash acquired————−4.7—————
Cash from investing activities−0.0−0.2−0.46371−78−1.3−1.6−0.5−0.2
Debt issued————78——72101.3
Shares issued9.13.4191.0411598.43030—
Cash from financing activities−12308.5−7.9431619.012410467
Change in cash−440.3−20−245.1−8.3−85686940
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at Kala Pharmaceuticals#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$907 K
Avraham Minkowitz
Other top executives, average
$2.4 M
the CEO earned 0.4× this
$100 invested is now
$1
Kala Pharmaceuticals: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Avraham Minkowitz$907 K−$1.0 M$2.4 M$1
2024Avraham Minkowitz$1.5 M$1.3 M$935 K$7
2023Avraham Minkowitz$8.3 M$3.7 M$2.9 M$2

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Kala Pharmaceuticals#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Auditor changedFiling
  • Auditor changedFiling
  • Delisting noticeFiling
  • Debt called earlyFiling

Delisting notice 3 · Auditor changed 2 · Debt called early 1 · Restructuring 3 · Change in control 1 · Directors and officers 8 · Material agreement 8 · Agreement ended 1 · New debt 2 · Unregistered share sale 5 · Shareholder rights changed 2 · Bylaws or fiscal year changed 4 · Shareholder vote 2 · Results announced 3

Kala Pharmaceuticals: events reported to the SEC
FiledWhat happenedFiling
Shareholder rights changedBylaws or fiscal year changed8-K
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Delisting notice8-K
Shareholder rights changedBylaws or fiscal year changed8-K
Material agreementUnregistered share sale8-K
Directors and officers8-K
Directors and officers8-K
Change in controlDirectors and officersMaterial agreementUnregistered share saleBylaws or fiscal year changedShareholder vote8-K
Delisting notice8-K
Material agreement8-K
Material agreementUnregistered share sale8-K
Auditor changedDirectors and officers8-K
Auditor changed8-K
Material agreement8-K
Directors and officersMaterial agreementAgreement endedNew debtUnregistered share saleBylaws or fiscal year changed8-K
Delisting notice8-K
Material agreementNew debtUnregistered share sale8-K
RestructuringDirectors and officers8-K
RestructuringDirectors and officers8-K/A
Debt called early8-K
Restructuring8-K
Directors and officers8-K
Results announced8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

7 private funding rounds before listing

Private share sales · funding history

Private share sales of Kala Pharmaceuticals
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2026$2 MPrivate placement after listingUnder $2 million1equitySEC
Jan 2026$2 MPrivate placement after listing$2 to $10 million20equitySEC
Dec 2024$11 MPrivate placement after listing$10 to $50 million6equitySEC
Jun 2024$13 MPrivate placement after listing$10 to $50 million5equitySEC
Nov 2021$16 MPrivate placement after listing$10 to $50 million26equitySEC
Apr 2016$68 MNo. 7$50 to $250 million25equitySEC
Aug 2015$7 MNo. 6$2 to $10 million1equitySEC
Apr 2014$23 MNo. 5$10 to $50 million16equitySEC
Feb 2013$6 MNo. 4$2 to $10 million10equitySEC
Feb 2012$7 MNo. 3$2 to $10 million10equitySEC
Oct 2010$3 MNo. 2$2 to $10 million9equity, debtSEC
Dec 2009$2 MNo. 1$2 to $10 million10equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at Kala Pharmaceuticals#

1 labor condition applications certified in fiscal 2021 for 1 positions, at a median wage of $220 K a year.

Certified, FY2021
1
#1,997 among companies on value.today
Worker positions
1
Median wage offered
$220 K
a year, full-time
Applications filed
1
Kala Pharmaceuticals: most frequent H-1B job titles in fiscal 2021
Job titlePositionsMedian wage offered
Director, External ManufacturingIndustrial Engineers1$220 K

Where: Bedford, MA 1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Kala Pharmaceuticals, Inc.

Layoffs at Kala Pharmaceuticals#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
132
2022–2025
Latest
—
2025-10-19
Kala Pharmaceuticals: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2025········19···19
2022······113·····113
Kala Pharmaceuticals: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
19 peopleRestructuring planSEC 8-K“In connection with such decisions, the Board approved a reduction in the Company’s workforce by approximately 19 employees, or approximately 51% (the “Reduction”).”Filing
19 peopleRestructuring planSEC 8-K“In connection with such decisions, the Board approved a reduction in the Company’s workforce by approximately 19 employees, or approximately 51% (the “Reduction”).”Filing
113 peopleRestructuring planSEC 8-K“On June 16, 2022, the Board of Directors (the “Board”) of the Company committed to a course of action to terminate 113 employees, consisting of the Company’s entire commercial sale…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Kala Pharmaceuticals compares in Biotechnology

  • Market cap$3 M · higher than 3% of 726
  • Revenue growth-65.4% · higher than 13% of 438
  • Price / book0.5× · lower than 92% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Kala Pharmaceuticals🇺🇸$3 M——-65.4%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 29, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Kala Pharmaceuticals? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Kala Pharmaceuticals's ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Kala Pharmaceuticals? Suggest a correction